Mortality and costs of acute renal failure associated with amphotericin B therapy (Q32068576)

6 July 2017

title

Mortality and costs of acute renal failure associated with amphotericin B therapy (English)

1 reference

6 July 2017

1 reference

Bates DW

1 reference

6 July 2017

Su L

1 reference

6 July 2017

Yu DT

1 reference

6 July 2017

Chertow GM

1 reference

6 July 2017

Seger DL

1 reference

6 July 2017

Gomes DR

1 reference

6 July 2017

Dasbach EJ

1 reference

6 July 2017

Platt R

1 reference

6 July 2017

language of work or name

English

0 references

publication date

21 February 2001

1 reference

Clinical Infectious Diseases

6 July 2017

published in

1 reference

6 July 2017

1 reference

6 July 2017

1 reference

6 July 2017

page(s)

686-693

1 reference

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

6 July 2017

cites work

1 reference

Hospital-acquired fungemia. Its natural course and clinical significance

21 January 2018

1 reference

Renal Tubular Acidosis Due to Amphotericin B

21 January 2018

1 reference

Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function

21 January 2018

1 reference

Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients

21 January 2018

1 reference

Amphotericin B use in a community hospital, with special emphasis on side effects

21 January 2018

1 reference

21 January 2018

1 reference

Systemic antifungal agents. Drug interactions of clinical significance

21 January 2018

1 reference

Drug-induced nephrotoxicity. Aetiology, clinical features and management

21 January 2018

1 reference

Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability.

21 January 2018

1 reference

Risk factors for Amphotericin B-associated nephrotoxicity

21 January 2018

1 reference

Sodium protects against nephrotoxicity in patients receiving amphotericin B.

21 January 2018

1 reference

Effect of salt supplementation on amphotericin B nephrotoxicity

21 January 2018

1 reference

Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis

21 January 2018

1 reference

AmBisome (liposomal amphotericin B): a comparative review.

21 January 2018

1 reference

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group

21 January 2018

1 reference

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients

21 January 2018

1 reference

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

Risk factors for acute renal insufficiency in patients with suspected or documented bacterial pneumonia.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/319211

1 reference

6 July 2017

1 reference